Eisai enters license deals for Latin America and Japan

5 October 2017

Japanese drug major Eisai’s (TYO: 4523) US subsidiary has signed an exclusive licensing agreement with Uruguay-headquartered Grupo Biotoscana for Eisai's oncology and neurology products in Latin America.

Under the terms of the agreement, Eisai Inc grants Biotoscana an exclusive license to seek regulatory approvals and commercialize the anticancer agents Halaven (eribulin) and Lenvima (lenvatinib), as well as antiepileptic agents Fycompa (perampanel) and Inovelon (rufinamide) in Latin America. In Mexico, however, Eisai will retain the rights to, and conduct all activities for, Halaven and Lenvima. Eisai Inc will supply Biotoscana with the products, for which it will receive compensation, and is also entitled to a one-time payment as well as milestone payments.

Sato Pharma to co-promote antifungal fosravuconazole in Japan

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK